Erica Lynn Wheeler, LMSW-CC, LADC, CCS | |
30 Leavitt St, Skowhegan, ME 04976-1843 | |
(207) 399-8678 | |
(844) 331-2315 |
Full Name | Erica Lynn Wheeler |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 30 Leavitt St, Skowhegan, Maine |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1366163628 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | LC8584 (Maine) | Secondary |
1041C0700X | Social Worker - Clinical | MC22037 (Maine) | Primary |
Mailing Address | Practice Location Address |
---|---|
Erica Lynn Wheeler, LMSW-CC, LADC, CCS 30 Leavitt St, Skowhegan, ME 04976-1843 Ph: (207) 399-8678 | Erica Lynn Wheeler, LMSW-CC, LADC, CCS 30 Leavitt St, Skowhegan, ME 04976-1843 Ph: (207) 399-8678 |
News Archive
The University of Manchester, GlaxoSmithKline and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research, a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of -5M from each partner over a three year period.
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
It is projected that up to 152 million people worldwide will be living with Alzheimer's disease (AD) by 2050. To date there are no drugs that have a substantial positive impact on either the prevention or reversal of cognitive decline.
Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital molecular imaging systems, announced today that it has signed an exclusive license and commercialization agreement with Mayo Clinic to further develop and commercialize a suite of technologies invented by a team of Mayo physicians and scientists, headed by Michael O'Connor, PhD.
› Verified 2 days ago